NCT03798080 - Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin | Biotech Hunter

Enrollment

426

Participants

Timeline

Start Date

February 19, 2019

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Insulin glargine/Lixisenatide (HOE901/AVE0010)

"Pharmaceutical form: solution~Route of administration: subcutaneous"

DRUG

Insulin glargine (HOE901)

"Pharmaceutical form: solution~Route of administration: subcutaneous"

DRUG

Metformin

"Pharmaceutical form: tablet~Route of administration: oral"

Trial Locations (45)

100034

Investigational Site Number 1560001, Beijing

102218

Investigational Site Number 1560039, Beijing

110004

Investigational Site Number 1560012, Shenyang

121000

Investigational Site Number 1560026, Jinzhou

130033

Investigational Site Number 1560005, Changchun

130041

Investigational Site Number 1560054, Changchun

200240

Investigational Site Number 1560011, Shanghai

201700

Investigational Site Number 1560002, Shanghai

210008

Investigational Site Number 1560028, Nanjing

210011

Investigational Site Number 1560013, Nanjing

210029

Investigational Site Number 1560017, Nanjing

225001

Investigational Site Number 1560023, Yangzhou

226001

Investigational Site Number 1560046, Nantong

230022

Investigational Site Number 1560021, Hefei

250000

Investigational Site Number 1560040, Jinan

250013

Investigational Site Number 1560007, Jinan

266003

Investigational Site Number 1560037, Qingdao

300121

Investigational Site Number 1560006, Tianjin

337055

Investigational Site Number 1560008, Pingxiang

354200

Investigational Site Number 1560025, Fuzhou

400010

Investigational Site Number 1560030, Chongqing

410013

Investigational Site Number 1560015, Changsha

412007

Investigational Site Number 1560022, Zhuzhou

475000

Investigational Site Number 1560042, Kaifeng

510080

Investigational Site Number 1560016, Guangzhou

Investigational Site Number 1560053, Guangzhou

510515

Investigational Site Number 1560045, Guangzhou

643002

Investigational Site Number 1560052, Zigong

650032

Investigational Site Number 1560003, Kunming

730000

Investigational Site Number 1560032, Lanzhou

810007

Investigational Site Number 1560020, Xining

810016

Investigational Site Number 1560050, Xining

830000

Investigational Site Number 1560049, Ürümqi

014010

Investigational Site Number 1560044, Baotou

Unknown

Investigational Site Number 1560010, Chenzhou

Investigational Site Number 1560019, Huanggang

Investigational Site Number 1560041, Jiaxing

Investigational Site Number 1560033, Luoyang

Investigational Site Number 1560035, Nanjing

Investigational Site Number 1560038, Nanjing

Investigational Site Number 1560031, Qinhuangdao

Investigational Site Number 1560027, Shanghai

Investigational Site Number 1560047, Shanghai

Investigational Site Number 1560036, Xuzhou

010017

Investigational Site Number 1560018, Hohhot